The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex, Vaiomer and Inserm to present at the IDF 2017 in Abu Dhabi, United Arab Emirates, Dec. 4-8, 2017

News detail

Return to all news & events

12/01/2017 Physiogenex, Vaiomer and Inserm to present at the IDF 2017 in Abu Dhabi, United Arab Emirates, Dec. 4-8, 2017

New data dealing with the effects of GLP-1 receptor agonists on gut microbiome and intestinal immune system in DIO mice will be presented – see the abstract.

The study will be presented by Dr. François Briand, Director of Research and Business Development at Physiogenex, during the poster session on Tuesday December the 5th, 2017, 11:45 to 12:45.

If you want to set an appointment during IDF 2017 with Dr. François Briand and/or discuss about your preclinical drug development program, please contact us!